I think one of the hardest things about trying to do “team-based” outpatient medicine is how hard it is to get a hold of outside docs sometimes… anyway feeling very thankful this morning with an exceptional communicator to help with care of a complex pt together 😄 #MedTwitter

Women are amazing #MedTwitter

This is great 👏🏻

“It just smells illegal” chadi nabhan MD, MBA, FACP 😂 - great podcast Aaron Goodman - “Papa Heme”

Couldn’t have said better myself. Wise thread by Vincent Rajkumar. #endmoc American Board of Internal Medicine (ABIM) #MedTwitter

Would love to see a larger trial but encouraging results from this small feasibility study: Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancy #cllsm ashpublications.org/bloodadvances/…

Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies ashpublications.org/blood/article-…

Taking a break from #AACR24 to watch a (significantly) more athletic C.C. (Caitlyn Clark) Taylor Lab UM Hai Dang Nguyen, PhD

Off to a great start in room 6D - come join to learn more about CH! Kelly Bolton MD PhD #AACR 24 #AACR

🫠 kinda not surprising at all but I gotta say, my own experiences have not been negative with my male colleagues (I might be a bit of a dodgy type with academic “scut work” though)

This 👇🏼 (and yes San Diego is a fickle mistress weather wise…)

Pre-gaming for the clonal hematopoiesis education session tomorrow! #AACR2024 #AACR24

Interesting strategy of CD30 CAR as consolidation after ASCT for high risk Hodgkin, T-cell and grey zone lymphoma (CD30+).

Hard to know what contribution the CAR have to the median PFS of 32 months. #lymsm

thelancet.com/journals/lanha…

As a former chemist-in-training (many don’t know I was in chemistry grad school prior to medicine), was a joy to be interviewed for c&en! #cllsm

Excited about this study and we are now open to accrual at UCI as well!

Well this is exciting news for immunosuppressed patients 👍🏻

Great poll… I’ve been thinking lately, what a shame that the phase 3 for liso-cel is using such a outdated control arm (idelaR or BR 💩), now that pirto is effectively the standard of care for double refractory patients.

Wow the FDA has been on a roll

Master the art of #BTKi sequencing in R/R #CLL . Watch our newest CME/MOC/NCPD/CPE/AAPA/IPCE activity, developed in collaboration with @CLLSociety, to hear expert discussion on sequential treatment planning bit.ly/46mbcMz #MedEd #MedTwitter calliecoombs

Not good enough. The people want NO LKA/MOC. CME is enough. Aaron Goodman - “Papa Heme”